Drug intelligence / Profile preview

SRD-441

Development stage: Phase 2
Lead developer: Serentis
Modality: Small Molecules
Administration: Topical

Overview

SRD-441 is a small molecule drug developed as a protease inhibitor for the treatment of atopic dermatitis. Its mechanism of action involves inhibition of matrix metalloproteinases (MMPs) and aureolysin, enzymes implicated in skin inflammation and barrier dysfunction. The drug was initially developed by Serentis and later associated with Surface Therapeutics. Clinical development reached Phase 2 trials for atopic dermatitis in several European countries but did not demonstrate efficacy in clinical studies[1][3][4][8].

Brand names: Aureostat
Other names: Protease inhibitor (atopic dermatitis)

Targets

AureolysinMMP12 (Macrophage Metalloelastase)

Beyond the preview

Go deeper on SRD-441.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRD-441.

Explore the full profile